⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of STAR Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
STAR Therapeutics
↗South San Francisco, CA 94080, USA
STAR Therapeutics is a clinical-stage biotechnology company founded in 2018 and headquartered in South San Francisco, California. The company's mission is to transform the lives of patients with serious diseases by discovering and developing best-in-class monoclonal antibody therapies, with initial focus on hematology and immunology. STAR employs an innovative hub-and-spoke business model that identifies rare diseases sharing common biology and develops single therapeutic solutions to treat multiple conditions. The company operates through subsidiary companies including ELECTRA Therapeutics (focused on SIRP proteins and immune system modulation) and Vega Therapeutics (advancing VGA039 for bleeding disorders). STAR's lead program, VGA039, is a first-in-class monoclonal antibody targeting Protein S designed to restore hemostatic balance and treat multiple bleeding disorders, with particular advancement in von Willebrand disease.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Monoclonal antibodies, Rare disease therapeutics
SIZE & FINANCIALS
Employees:51-200
Founded:2018
Ownership:private
Status:operating
FUNDING
Stage:Series D
Total Raised:$315M+
Investors:Sanofi Ventures (co-lead Series D), Viking Global Investors (co-lead Series D), Janus Henderson Investors, Frazier Life Sciences, GordonMD Global Investments, 18 total investors in Series D round
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Monoclonal antibodies (mAb)
Active Trials:1
Trial Phases:Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:ELECTRA Therapeutics (SIRP-focused, ~$84M+ Series B funding), Vega Therapeutics (VGA039 development)
Key Partnerships:Sanofi Ventures (Board representation: Jason Hafler, PhD), Viking Global Investors (Board observer: Maneka Mirchandaney)
COMPETITION
Position:Emerging|Challenger
Competitors:Bayer AG, CSL Behring, Ferring Pharmaceuticals, Grifols, Octapharma AG, Pfizer, Sanofi, Takeda +5 more
LEADERSHIP
Key Executives:
Adam Rosenthal, PhD - CEO & Founder
Sandip Panicker, PhD - Chief Scientific Officer
Gary Patou, MD - Chief Medical Officer
Kathy Dong, PharmD, MBA - Chief Operating Officer
Scott Robertson - Chief Financial Officer & Chief Business Officer
Michelle Carpenter, JD, RAC - Executive Vice President, Regulatory Affairs & Project Management
Scientific Founders:Adam Rosenthal, PhD
Board Members:Adam Rosenthal, PhD (CEO & Founder), Beth Seidenberg, MD (Founding Managing Director, Westlake Village BioPartners), Carl Gordon, PhD, CFA (Managing Partner, OrbiMed), Vijay Lathi (Managing Director, New Leaf Venture Partners), Nancy Stagliano, PhD (Executive Board Chair), Jason Hafler, PhD (Sanofi Ventures, joined in Series D)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with STAR Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.